目的探讨B细胞异位基因2(B cell translocation gene 2,BTG2)在原发性肝细胞癌中的表达及与术后生存期之间的关系。方法共纳入125例可手术切除的原发性肝细胞癌患者,其中有完整随访记录101例;用免疫组化方法检测患者肿瘤组织中BTG2蛋白的表达,并分为3组:BTG2高表达组,BTG2蛋白中表达(++)或强表达(+++);BTG2低表达组,BTG2蛋白低表达(+);BTG2阴性组,BTG2蛋白无表达(-)。分析BTG2表达水平与临床病理因素和术后总生存期的相关性。选取12对癌与癌旁配对组织,用RT-PCR检测其BTG2表达水平。结果 125例癌组织中,BTG2阴性组、低表达组和高表达组分别为106、13、6例;癌旁组织中,BTG2阴性组、低表达组和高表达组分别为41、14、22例,癌与癌旁组织BTG2表达差异有统计学意义(χ~2=28.102,P<0.001)。RT-PCR检测结果显示12对癌与癌旁配对组织中,癌组织BTG2表达水平低于癌旁的有8例。癌栓发生与BTG2表达有明显相关性(χ~2=8.305,P=0.013),其中低表达组癌栓发生率最高。BTG2低表达组中位总生存期为36个月(95%CI:8.437~63.564),而高表达和阴性表达组未达到中位总生存期(Log-Rankχ~2=4.512,P=0.105)。亚组分析表明,BTG2高表达组患者总生存期显著长于低表达组(χ~2=4.266,P=0.039),而高表达与阴性组(χ~2=2.729,P=0.099)以及低表达与阴性组(χ~2=1.400,P=0.237)之间差异没有统计学意义。逐步Cox回归分析结果显示,分化程度、肝硬化、癌栓和转移情况是总生存期的独立预后因素。结论 BTG2蛋白在原发性肝细胞癌中的表达呈低表达,并且BTG2蛋白的高表达提示肝癌患者预后较好,可作为肝细胞癌的潜在预后指标。 Objective To investigate the expression of B cell translocation gene 2 (BTG2) in primary hepatocellular carcinoma and its relationship with postoperative survival. METHODS: A total of 125 patients with resectable primary hepatocellular carcinoma (HCC) were enrolled. Among them, 101 patients had complete follow-up records. The expression of BTG2 protein in tumor tissues was detected by immunohistochemistry and divided into three groups: BTG2 overexpression group , BTG2 protein (++) or strong expression (+++); BTG2 low expression group, BTG2 protein low expression (+); BTG2 negative group, BTG2 protein no expression (-). The correlation between BTG2 expression and clinicopathological parameters and postoperative survival was analyzed. Twenty pairs of cancer and para-cancerous paired tissues were selected and the expression of BTG2 was detected by RT-PCR. Results Among the 125 cases of cancerous tissues, there were 106, 13, and 6 cases in the BTG2 negative group, the low expression group and the high expression group respectively. In the paracancerous tissues, the BTG2 negative group, the low expression group and the high expression group were 41,14,22 For example, there was significant difference in the expression of BTG2 between cancer and adjacent tissues (χ ~ 2 = 28.102, P <0.001). The results of RT-PCR showed that the expression of BTG2 in cancer tissues and paracancerous tissues was lower than that in adjacent tissues in 12 pairs of cancer tissues and in 8 adjacent tissues. There was a significant correlation between the occurrence of tumor emboli and the expression of BTG2 (χ ~ 2 = 8.305, P = 0.013). The incidence of tumor emboli in the low expression group was the highest. The median overall survival was 36 months in the BTG2 low expression group (95% CI: 8.437 to 63.564) whereas the median overall survival was not reached in the high and negative expression groups (Log-Rankχ2 = 4.512, P = 0.105) . Subgroup analysis showed that the overall survival of patients with BTG2 overexpression was significantly longer than that of patients with low expression (χ ~ 2 = 4.266, P = 0.039), while the high expression and negative patients (χ ~ 2 = 2.729, And negative group (χ ~ 2 = 1.400, P = 0.237), the difference was not statistically significant. Stepwise Cox regression analysis showed that the degree of differentiation, cirrhosis, thrombus and metastasis were independent prognostic factors of overall survival. Conclusions The expression of BTG2 protein is low in primary hepatocellular carcinoma, and the high expression of BTG2 protein suggests that the prognosis of patients with hepatocellular carcinoma is good and may be used as a potential prognostic indicator for hepatocellular carcinoma.